Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotection and dopamine agonists.

Anthony H V Schapira1

  • 1University Department of Clinical Neurosciences, Royal Free and University College Medical School, and the Institute of Neurology, University College London, London, UK. schapira@rfc.ucl.ac.uk

Neurology
|March 23, 2002
PubMed
Summary

Parkinson's disease (PD) involves dopaminergic cell death. Dopamine agonists, particularly pramipexole, show promise not only for symptom relief but also for potential neuroprotection by preserving neurons and mitigating disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same author

GLP-1 and Parkinson's Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy.

Cells·2026
Same author

New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment.

The Lancet. Neurology·2026
Same author

Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals.

Nature medicine·2026
Same author

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

Journal of neurology·2026
Same author

Introducing PIGMO, a novel PIGmented MOuse model of Parkinson's disease.

NPJ Parkinson's disease·2026

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Parkinson's disease (PD) pathogenesis involves dopaminergic cell death in the substantia nigra, influenced by toxins (e.g., MPTP, rotenone), genetic factors, oxidative stress, mitochondrial dysfunction, and inflammation.
  • Emerging research highlights protein misfolding and aggregation pathways in PD.
  • Dopamine agonists are being investigated for their potential to modify PD's course by slowing cell death or restoring neuronal function.

Purpose of the Study:

  • To explore the neuroprotective properties of dopamine agonists beyond symptomatic relief in Parkinson's disease.
  • To investigate the specific neuroprotective mechanisms of the D(2)/D(3) dopamine agonist pramipexole.

Main Methods:

  • Review of existing literature on factors inducing dopaminergic cell death and PD pathogenesis.

Related Experiment Videos

  • Analysis of in vitro and in vivo studies examining the effects of dopamine agonists, including pramipexole, on neuronal survival and function.
  • Examination of evidence for pramipexole's actions on mitochondrial membrane potential and apoptosis.

    • Main Results:

    • Dopamine agonists demonstrate antioxidant actions and may reduce motor complications associated with levodopa.
    • Pramipexole exhibits neuroprotective effects in cellular and animal models against toxins like MPTP and 6-hydroxydopamine.
    • These protective effects may involve direct actions on mitochondrial membrane potential and inhibition of apoptosis.

    Conclusions:

    • Dopamine agonists, especially pramipexole, show potential for neuroprotection in Parkinson's disease, possibly through mechanisms independent of dopamine agonism.
    • Further clinical confirmation of pramipexole's neuroprotective effects could support its early use in PD management.